Authors' picture

By Experimentica on April 12, 2021
Team

Summary: This year again the work of Experimentica's scientists at the forefront of Ophthalmology research will be featured at the 2021 ARVO Annual Meeting.

Content

ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. This year again the work of Experimentica’s scientists at the forefront of Ophthalmology research will be featured at the 2021 ARVO Annual Meeting.

Follow our Scientists and schedule a discussion with the team during the Meeting!

Featured abstracts and posters


Do not miss out on our team’s Posters and Abstracts in physiopathology, preclinical model development, and artificial intelligence.

P O S T E R

Validation of a novel artificial intelligence (AI) machine learning algorithm for quantification of vascular pathology in preclinical model

May 1, 2021, 12:15pm EDT | Add to Calendar

Authors: Jonas Jarutis | Simas Bijeikis | Symantas Ragauskas | Kernius Mickevicius | Giedrius Kalesnykas | Marc Cerrada-Gimenez | Simon Kaja | Nerija Kvietkauskiene

To validate a novel artificial intelligence (AI) machine learning algorithm for the automated quantification of lesion size in the mouse choroidal neovascularization (CNV) model.

A R T I C L E

Extracellular vesicles (exosomes) derived from primary optic nerve head astrocytes enhance neurite outgrowth

May 3, 2021, 4:30pm EDT | Add to Calendar

Authors: Simon Kaja | Harsh Hariani | Anita Ghosh | Giedrius Kalesnykas | Walter K. Jones

To determine the properties of primary optic nerve head astrocyte (ONHA)-derived extracellular vesicles (exosomes), their uptake into primary neurons, and to identify the functional effects of exosomes on neuronal survival and neurite outgrowth.

P O S T E R

Effects of chronic alcohol administration on the cornea in preclinical models

May 5, 2021, 2:45pm EDT | Add to Calendar

Authors: Anita Ghosh | Robertas Cesna | Agne Ziniauskaite | Donatas Neverauskas | Jonathan Eby | Symantas Ragauskas | Simon Kaja

There is a clinical association between acute and chronic alcohol consumption and the incidence of ocular surface disease, including dry eye disease. The goal of this study was to investigate if chronic moderate alcohol consumption leads to signs of DED in vivo, and to investigate oxidative stress pathways involved in alcohol-induced damage to human corneal epithelial cells in vitro.

P O S T E R

Maturation of retinal pigment epithelium cells in vitro enhances the endogenous antioxidant defense system

May 5, 2021, 2:45pm EDT | Add to Calendar

Authors: Jenni J. Hakkarainen | Olga Vergun | Anita Ghosh | Simon Kaja

The aim of the study was to evaluate the endogenous antioxidant defense system in human induced pluripotent stem cell (hiPSC)-derived retinal pigment epithelium (RPE) cells.

Schedule time with us during ARVO


Whether you have a question about our science, preclinical models, capabilities, pricing or anything else, our senior management and business development team is ready to answer your inquiries.

Giedrius Kalesnykas, PhD

President and Chief Executive Officer

Dr. Kalesnykas has extensive research experience in eye research and neuroscience developing neuronal-based projects at the University of Eastern Finland and The Wilmer Eye Institute, The Johns Hopkins University, MD, USA. For more info visit Giedrius’ profile page or LinkedIn.

Simon Kaja, PhD

Chief Scientific Officer, VP Americas

Dr. Kaja is an internationally recognized expert in experimental ophthalmology and neuroscience and a regular consultant to both pharma and biotech companies. He has published over 50 peer-reviewed articles and book chapters. For more info visit Simon’s profile page or LinkedIn.

Jenni J. Hakkarainen, PhD

Chief Operating Officer

Dr. Hakkarainen has a strong research background in ex vivo and in vitro drug permeability testing and prediction of drug transport across biological barriers, such as cornea, blood-brain barrier, intestine, and skin. For more info visit Jenni’s profile page or LinkedIn.

Guillaume Demarne, PharmD

Director of Business Development

Dr. Demarne has been leading and involved in pharmaceutical operations, fundraising, and business development for 15 years at international research institutes, biotech start-ups, and pharmaceutical companies in Europe, the U.S., and China. For more info visit Guillaume’s profile page or LinkedIn.

Schedule a Teams meeting with us during or after the 2021 ARVO Annual Meeting using the calendar below.

Interested in a specific topic?

Our dedicated in-house experts are here to help. Reach out to them directly.

Large animal in vivo studies (e.g. minipigs) | Book a meeting

In vitro and ex vivo studies | Book a meeting

Find out more


Authors' picture